Joseph S. Durgin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Joseph S. Durgin has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Paul William Harms
Department of Pathology University of Michigan Ann Arbor Michigan USA
5 shared publications Emily H. Smith
Department of Dermatology Saint Louis University School of Medicine St. Louis Missouri USA
3 shared publications- Megan Hauptman
Department of Dermatology, University of Michigan, Ann Arbor, MI, USA
3 shared publications - Mio Nakamura
Department of Dermatology, University of Michigan, Ann Arbor, MI, USA
3 shared publications - Scott C. Bresler
Department of Pathology University of Michigan Ann Arbor Michigan USA
3 shared publications - Sunny Y. Wong
Department of Dermatology, Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, USA.
3 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Springer Nature in EMBO Molecular Medicine
N-Myc promotes a proliferative progenitor-like cell state to drive basal cell carcinoma progression
Driver mutations that activate upstream Hedgehog (Hh) signaling are well-known to initiate basal cell carcinoma (BCC); however, the role of recurrent secondary mutations is less well understood. Here, we performed spatial transcriptomics to show that nascent murine BCC-like tumors are initially comprised of two subpopulations that differ in expression of Hh, stem cell, and differentiation markers. Using a newly developed cell culture formulation that we termed “RRi conditions”, we established several mouse BCC cell lines, benchmarked them against existing ASZ BCC cells, and identified novel genes associated with Hh activation ( Wnt7b , Tgfb3 , Cxcl14 ). We further show that inducible N-MYC expression promotes an NICD low ;K10 low ;Ki67+ undifferentiated cell state, similar to that of transit-amplifying hair follicle progenitors, and that genetically ablating N-Myc blunts tumor formation in mice. Finally, we report that an immunomodulatory drug, imiquimod, regresses nascent lesions and destabilizes N-MYC protein, an effect that depends upon GSK3 and proteasome activity. Altogether, our findings demonstrate that BCCs upregulate N-MYC to maintain a proliferative progenitor-like cell state, and support the use of imiquimod to restrict tumor progression.
- 9 November 2026
- Published by Springer Nature in EMBO Molecular Medicine
Open AccessN-Myc promotes a proliferative progenitor-like cell state to drive basal cell carcinoma progression
Driver mutations that activate upstream Hedgehog (Hh) signaling are well-known to initiate basal cell carcinoma (BCC); however, the role of recurrent secondary mutations is less well understood. Here, we performed spatial transcriptomics to show that nascent murine BCC-like tumors are initially comprised of two subpopulations that differ in expression of Hh, stem cell, and differentiation markers. Using a newly developed cell culture formulation that we termed “RRi conditions”, we established several mouse BCC cell lines, benchmarked them against existing ASZ BCC cells, and identified novel genes associated with Hh activation ( Wnt7b , Tgfb3 , Cxcl14 ). We further show that inducible N-MYC expression promotes an NICD low ;K10 low ;Ki67+ undifferentiated cell state, similar to that of transit-amplifying hair follicle progenitors, and that genetically ablating N-Myc blunts tumor formation in mice. Finally, we report that an immunomodulatory drug, imiquimod, regresses nascent lesions and destabilizes N-MYC protein, an effect that depends upon GSK3 and proteasome activity. Altogether, our findings demonstrate that BCCs upregulate N-MYC to maintain a proliferative progenitor-like cell state, and support the use of imiquimod to restrict tumor progression.
- Open Access
- 5 November 2026
- Published by Wiley in Journal of Cutaneous Pathology
Diagnostic Utility of p16 and MTAP Immunohistochemistry for Cellular Neurothekeomas
Aims: Cellular neurothekeoma (cNTK) is a benign cutaneous tumor of uncertain histogenesis. Recent genomic characterization identified recurrent deletions on chromosome 9p21.3, encompassing CDKN2A (p16), as a primary driver event in cNTK. We assessed the potential utility of p16 and MTAP immunohistochemistry for discriminating cNTKs from morphologic mimics. Methods and Results: Immunohistochemistry for p16 and MTAP was performed on 21 and 19 cNTKs, respectively, and a broad comparison group of fibrohistiocytic neoplasms. Staining distribution was scored semi‐quantitatively. Low/absent p16 expression (Score 1) was observed in 17 of 21 (81%) cNTK cases. Low/absent p16 was significantly more likely in cNTK relative to atypical fibrous histiocytoma, dermatofibroma, Langerhans cell histiocytosis, and pleomorphic dermal sarcoma. However, there was no statistical difference relative to some other tumor types, including plexiform fibrohistiocytic tumor or atypical fibroxanthoma. Only 26% of assessed cNTK cases (5/19) showed loss of MTAP; this did not reach statistical significance relative to other tumor types. Conclusions: Low/absent p16 expression is common in cNTKs, corroborating recent genetic evidence for 9p21.3 deletion. Diagnostic utility of low/absent p16 varied, with high specificity in comparison to atypical fibrous histiocytoma and low utility for plexiform fibrohistiocytic tumor. Despite its proximity to CDKN2A on 9p21.3, MTAP immunohistochemistry shows low sensitivity for cNTKs, with diminished staining in only a small subset of tumors. Our findings suggest that low/absent p16 can be diagnostically informative for cNTK in certain contexts; however, low specificity against some tumor types is an important limitation.
- 5 November 2026
- Published by Wiley in Journal of Cutaneous Pathology
Open AccessDiagnostic Utility of p16 and MTAP Immunohistochemistry for Cellular Neurothekeomas
Aims: Cellular neurothekeoma (cNTK) is a benign cutaneous tumor of uncertain histogenesis. Recent genomic characterization identified recurrent deletions on chromosome 9p21.3, encompassing CDKN2A (p16), as a primary driver event in cNTK. We assessed the potential utility of p16 and MTAP immunohistochemistry for discriminating cNTKs from morphologic mimics. Methods and Results: Immunohistochemistry for p16 and MTAP was performed on 21 and 19 cNTKs, respectively, and a broad comparison group of fibrohistiocytic neoplasms. Staining distribution was scored semi‐quantitatively. Low/absent p16 expression (Score 1) was observed in 17 of 21 (81%) cNTK cases. Low/absent p16 was significantly more likely in cNTK relative to atypical fibrous histiocytoma, dermatofibroma, Langerhans cell histiocytosis, and pleomorphic dermal sarcoma. However, there was no statistical difference relative to some other tumor types, including plexiform fibrohistiocytic tumor or atypical fibroxanthoma. Only 26% of assessed cNTK cases (5/19) showed loss of MTAP; this did not reach statistical significance relative to other tumor types. Conclusions: Low/absent p16 expression is common in cNTKs, corroborating recent genetic evidence for 9p21.3 deletion. Diagnostic utility of low/absent p16 varied, with high specificity in comparison to atypical fibrous histiocytoma and low utility for plexiform fibrohistiocytic tumor. Despite its proximity to CDKN2A on 9p21.3, MTAP immunohistochemistry shows low sensitivity for cNTKs, with diminished staining in only a small subset of tumors. Our findings suggest that low/absent p16 can be diagnostically informative for cNTK in certain contexts; however, low specificity against some tumor types is an important limitation.
- 9 October 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (12) , 1534-1541
Clinicopathological Characteristics of Merkel Cell Carcinoma in Younger Patients
Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine carcinoma that predominantly affects older adults. MCC arising in younger patients is exceedingly rare, and its clinicopathologic features remain poorly described. We retrospectively reviewed clinical records, histopathology, and outcomes of patients aged 18 to 50 years diagnosed with MCC at a single tertiary care center between 2009 and 2025. A total of 13 patients were identified with a median age of 40 years (range: 18 to 50 y); 61.5% were female. Of 11 patients with available data, 36.4% had pre-existing immune suppression. Tumors arose most commonly on the extremities (46.2%), followed by the head and neck (23.1%), trunk (15.4%), and unknown primary (15.4%). The most common growth pattern was nodular (63.6%), followed by infiltrative (27.3%). Median Breslow depth was 10.5 mm and median mitotic rate was 46/mm². Immunohistochemical staining was consistent with MCC in all cases. Merkel cell polyomavirus was detected by large T antigen chromogenic in situ hybridization and/or immunohistochemistry in 62.5% of assessable cases (5/8). Lymph node metastases were present at presentation in 60.0% of patients, and distant metastases developed in 54.5%. Kaplan–Meier estimated overall survival was 74.1% at 2 years and 59.3% at 5 years. In this single-institution cohort, early-onset MCC was associated with elevated rates of immune suppression and a substantial burden of regional and distant metastatic disease, highlighting clinicopathologic distinctions from predominantly older historical MCC populations.
- 9 October 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (12) , 1534-1541
Clinicopathological Characteristics of Merkel Cell Carcinoma in Younger Patients
Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine carcinoma that predominantly affects older adults. MCC arising in younger patients is exceedingly rare, and its clinicopathologic features remain poorly described. We retrospectively reviewed clinical records, histopathology, and outcomes of patients aged 18 to 50 years diagnosed with MCC at a single tertiary care center between 2009 and 2025. A total of 13 patients were identified with a median age of 40 years (range: 18 to 50 y); 61.5% were female. Of 11 patients with available data, 36.4% had pre-existing immune suppression. Tumors arose most commonly on the extremities (46.2%), followed by the head and neck (23.1%), trunk (15.4%), and unknown primary (15.4%). The most common growth pattern was nodular (63.6%), followed by infiltrative (27.3%). Median Breslow depth was 10.5 mm and median mitotic rate was 46/mm². Immunohistochemical staining was consistent with MCC in all cases. Merkel cell polyomavirus was detected by large T antigen chromogenic in situ hybridization and/or immunohistochemistry in 62.5% of assessable cases (5/8). Lymph node metastases were present at presentation in 60.0% of patients, and distant metastases developed in 54.5%. Kaplan–Meier estimated overall survival was 74.1% at 2 years and 59.3% at 5 years. In this single-institution cohort, early-onset MCC was associated with elevated rates of immune suppression and a substantial burden of regional and distant metastatic disease, highlighting clinicopathologic distinctions from predominantly older historical MCC populations.
- Open Access
- 13 September 2026
- Published by Wiley in Journal of Cutaneous Pathology
Utility of IL ‐18 Immunohistochemistry in Distinguishing Dermatomyositis and Lupus Erythematosus in Skin Biopsies
Background: Distinction of dermatomyositis ( DM ) and cutaneous lupus erythematosus ( LE ) in skin biopsies is often difficult due to significant histopathologic overlap. Prior transcriptional analysis has identified upregulation of IL ‐18 in DM compared with LE . We aimed to assess its utility as an immunohistochemical marker in this differential diagnosis. Methods: Skin biopsies classified as DM ( n = 35) or LE ( n = 32) were immunostained with an IL ‐18 antibody. A positive IL ‐18 result was defined as presence of full‐thickness epidermal staining of medium or strong intensity. Absent, weak, or partial‐thickness staining was considered negative. Results were compared between groups by Fisher's exact test. Results: IL ‐18 expression in keratinocytes, when present, was consistently cytoplasmic with or without nuclear positivity. Twenty‐eight (80%) DM cases and 11 (34%) LE cases were positive for IL ‐18 ( p = 0.0002). A positive result had a sensitivity of 80% and a specificity of 66% for DM . Specifically, strong full‐thickness staining was only observed in DM (five cases; p = 0.05), whereas complete absence of epidermal staining was seen exclusively in LE (five cases; p = 0.02). Conclusions: IL ‐18 immunohistochemistry can be a useful diagnostic adjunct in distinguishing DM and LE in a small subset of skin biopsies when staining is strong or completely absent. Correlation with clinical and histopathologic findings remains imperative.
- 13 September 2026
- Published by Wiley in Journal of Cutaneous Pathology
Open AccessUtility of IL ‐18 Immunohistochemistry in Distinguishing Dermatomyositis and Lupus Erythematosus in Skin Biopsies
Background: Distinction of dermatomyositis ( DM ) and cutaneous lupus erythematosus ( LE ) in skin biopsies is often difficult due to significant histopathologic overlap. Prior transcriptional analysis has identified upregulation of IL ‐18 in DM compared with LE . We aimed to assess its utility as an immunohistochemical marker in this differential diagnosis. Methods: Skin biopsies classified as DM ( n = 35) or LE ( n = 32) were immunostained with an IL ‐18 antibody. A positive IL ‐18 result was defined as presence of full‐thickness epidermal staining of medium or strong intensity. Absent, weak, or partial‐thickness staining was considered negative. Results were compared between groups by Fisher's exact test. Results: IL ‐18 expression in keratinocytes, when present, was consistently cytoplasmic with or without nuclear positivity. Twenty‐eight (80%) DM cases and 11 (34%) LE cases were positive for IL ‐18 ( p = 0.0002). A positive result had a sensitivity of 80% and a specificity of 66% for DM . Specifically, strong full‐thickness staining was only observed in DM (five cases; p = 0.05), whereas complete absence of epidermal staining was seen exclusively in LE (five cases; p = 0.02). Conclusions: IL ‐18 immunohistochemistry can be a useful diagnostic adjunct in distinguishing DM and LE in a small subset of skin biopsies when staining is strong or completely absent. Correlation with clinical and histopathologic findings remains imperative.
- Open Access
- 12 January 2026
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 9, e76674
Leveraging AI Large Language Models for Writing Clinical Trial Proposals in Dermatology: Instrument Validation Study
Background: Large language models (LLMs) are becoming increasingly popular in clinical trial design but have been underused in research proposal development. Objective: This study compared the performance of commonly used open access LLMs versus human proposal composition and review. Methods: A total of 10 LLMs were prompted to write a research proposal. Six physicians and each of the LLMs assessed 11 blinded proposals for capabilities and limitations in accuracy and comprehensiveness. Results: ChatGPT-o1 and Llama 3.1 were rated the most and least accurate, respectively, by human scorers. LLM scorers rated ChatGPT-o1 and DeepSeek R1 as the most accurate. ChatGPT-o1 and Llama 3.1 were rated as the most and least comprehensive, respectively, by human and LLM scorers. LLMs performed poorly on scoring proposals and, on average, rated proposals 1.9 points higher than humans for both accuracy and comprehensiveness. Conclusions: Paid versions of ChatGPT remain the highest-quality and most versatile option of the available LLMs. These tools cannot replace expert input but serve as powerful assistants, streamlining the development process and enhancing productivity.
- 12 January 2026
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 9, e76674
Open AccessLeveraging AI Large Language Models for Writing Clinical Trial Proposals in Dermatology: Instrument Validation Study
Background: Large language models (LLMs) are becoming increasingly popular in clinical trial design but have been underused in research proposal development. Objective: This study compared the performance of commonly used open access LLMs versus human proposal composition and review. Methods: A total of 10 LLMs were prompted to write a research proposal. Six physicians and each of the LLMs assessed 11 blinded proposals for capabilities and limitations in accuracy and comprehensiveness. Results: ChatGPT-o1 and Llama 3.1 were rated the most and least accurate, respectively, by human scorers. LLM scorers rated ChatGPT-o1 and DeepSeek R1 as the most accurate. ChatGPT-o1 and Llama 3.1 were rated as the most and least comprehensive, respectively, by human and LLM scorers. LLMs performed poorly on scoring proposals and, on average, rated proposals 1.9 points higher than humans for both accuracy and comprehensiveness. Conclusions: Paid versions of ChatGPT remain the highest-quality and most versatile option of the available LLMs. These tools cannot replace expert input but serve as powerful assistants, streamlining the development process and enhancing productivity.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Dermatological Medicine
- Vol. 2026 (1) , 6524620
Leukemia Cutis Exhibiting the Koebner Phenomenon: A Rare Clinical Presentation of Acute Myeloid Leukemia
Leukemia cutis with predilection for sites of prior cutaneous trauma, often described as a Koebner‐like phenomenon, is a rare but recognized occurrence. We present a unique case of an, otherwise, healthy male who developed leukemia cutis at a prior unrelated biopsy site, leading to a new diagnosis of acute myeloid leukemia (AML). Certain AML subtypes with extramedullary propensity, particularly M4 and M5, as seen in our patient, are associated with an increased risk of leukemia cutis. Unlike their medullary counterparts, extramedullary AML cells preferentially migrate to and persist in tissues outside the bone marrow, where the local microenvironment may promote immune escape. Although the localization of leukemia cutis to the biopsy site is consistent with a Koebner‐like response, it remains uncertain whether subclinical leukemic cells were already present at the time of the initial excision; therefore, a definitive causal relationship between trauma and leukemic infiltration cannot be established. Additionally, the prior keratoacanthoma and its excision may have created a localized immunocompromised cutaneous district, or locus minoris resistentiae , further predisposing the site to leukemic cell infiltration. The immunologic features of extramedullary AML, including impaired antigen presentation and T‐cell exhaustion, overlap with this concept of localized immune dysregulation and may have facilitated site‐specific leukemic infiltration. New infiltrative plaques at sites of prior skin trauma or biopsy warrant prompt biopsy and histopathological evaluation, even in patients without known hematologic malignancy. Leukemia cutis may represent the first manifestation of underlying acute leukemia, making early recognition critical for timely oncologic referral and treatment.
- 1 January 2026
- Published by Wiley in Case Reports in Dermatological Medicine
- Vol. 2026 (1) , 6524620
Open AccessLeukemia Cutis Exhibiting the Koebner Phenomenon: A Rare Clinical Presentation of Acute Myeloid Leukemia
Leukemia cutis with predilection for sites of prior cutaneous trauma, often described as a Koebner‐like phenomenon, is a rare but recognized occurrence. We present a unique case of an, otherwise, healthy male who developed leukemia cutis at a prior unrelated biopsy site, leading to a new diagnosis of acute myeloid leukemia (AML). Certain AML subtypes with extramedullary propensity, particularly M4 and M5, as seen in our patient, are associated with an increased risk of leukemia cutis. Unlike their medullary counterparts, extramedullary AML cells preferentially migrate to and persist in tissues outside the bone marrow, where the local microenvironment may promote immune escape. Although the localization of leukemia cutis to the biopsy site is consistent with a Koebner‐like response, it remains uncertain whether subclinical leukemic cells were already present at the time of the initial excision; therefore, a definitive causal relationship between trauma and leukemic infiltration cannot be established. Additionally, the prior keratoacanthoma and its excision may have created a localized immunocompromised cutaneous district, or locus minoris resistentiae , further predisposing the site to leukemic cell infiltration. The immunologic features of extramedullary AML, including impaired antigen presentation and T‐cell exhaustion, overlap with this concept of localized immune dysregulation and may have facilitated site‐specific leukemic infiltration. New infiltrative plaques at sites of prior skin trauma or biopsy warrant prompt biopsy and histopathological evaluation, even in patients without known hematologic malignancy. Leukemia cutis may represent the first manifestation of underlying acute leukemia, making early recognition critical for timely oncologic referral and treatment.
- Open Access
- 11 December 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (3)
Spatial transcriptomics identifies differentiation, lipid metabolism, and retinoid pathway alterations in acne vulgaris
Acne vulgaris is a common skin condition involving complex interactions among lipid-secreting sebaceous glands, keratinocytes, immune cells, and microbiota. While retinoids are effective for treating acne, disease pathogenesis remains poorly understood. In particular, it remains unclear how different subtypes of acne, including inflammatory (pustular) and noninflammatory (comedonal) lesions, vary in gene expression, signaling, and sebaceous gland involvement. Here, we performed spatial transcriptomics on healthy, nonlesional, comedonal, and pustular acne skin using a custom panel targeting sebaceous differentiation, lipid metabolism, and retinoid signaling pathways. We also designed a specialized segmentation pipeline to improve transcript assignment in the spatially complex sebaceous gland. Our analyses identified a PPARG + transitional basal cell state in sebocytes and revealed that comedonal skin upregulates sebogenesis genes, whereas pustular skin downregulates sebogenesis. Both lesion types exhibited increased AP-1 transcription factors and elevated FABP5, a chaperone that blunts retinoic acid receptor signaling. Finally, we demonstrated that an AP-1 inhibitor, T-5224, downregulates FABP5 in human keratinocytes and reduces pustule formation in a mouse model of high-fat diet–induced folliculitis. Altogether, these findings indicate that altered lipogenesis, retinoid signaling, and keratinocyte differentiation are key features of acne, and nominate AP-1 and FABP5 as potential therapeutic targets.
- 11 December 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (3)
Open AccessSpatial transcriptomics identifies differentiation, lipid metabolism, and retinoid pathway alterations in acne vulgaris
Acne vulgaris is a common skin condition involving complex interactions among lipid-secreting sebaceous glands, keratinocytes, immune cells, and microbiota. While retinoids are effective for treating acne, disease pathogenesis remains poorly understood. In particular, it remains unclear how different subtypes of acne, including inflammatory (pustular) and noninflammatory (comedonal) lesions, vary in gene expression, signaling, and sebaceous gland involvement. Here, we performed spatial transcriptomics on healthy, nonlesional, comedonal, and pustular acne skin using a custom panel targeting sebaceous differentiation, lipid metabolism, and retinoid signaling pathways. We also designed a specialized segmentation pipeline to improve transcript assignment in the spatially complex sebaceous gland. Our analyses identified a PPARG + transitional basal cell state in sebocytes and revealed that comedonal skin upregulates sebogenesis genes, whereas pustular skin downregulates sebogenesis. Both lesion types exhibited increased AP-1 transcription factors and elevated FABP5, a chaperone that blunts retinoic acid receptor signaling. Finally, we demonstrated that an AP-1 inhibitor, T-5224, downregulates FABP5 in human keratinocytes and reduces pustule formation in a mouse model of high-fat diet–induced folliculitis. Altogether, these findings indicate that altered lipogenesis, retinoid signaling, and keratinocyte differentiation are key features of acne, and nominate AP-1 and FABP5 as potential therapeutic targets.
- Open Access
- 28 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Leveraging Artificial Intelligence Large Language Models for Writing Clinical Trial Proposals in Dermatology (Preprint)
BACKGROUND Large language models (LLMs) are becoming increasingly popular in clinical trial design but have been underutilized in research proposal development. OBJECTIVE This study compares the performance of commonly used open access LLMs versus human proposal composition and review. METHODS Ten LLMs were prompted to write a research proposal. Six physicians and each of the LLMs assessed 11 blinded proposals for capabilities and limitations in accuracy and comprehensiveness. RESULTS Chat GPT o1 was rated the most accurate and LLaMA 3.1 the least accurate by human scorers. LLM scorers rated Chat GPT o1 and Deepseek R1 the most accurate. Chat GPT o1 was the most comprehensive and LLaMA 3.1 the least comprehensive by human and LLM scorers. LLMs performed poorly on scoring proposals, and on average rated proposals 1.9 points higher than humans for both accuracy and comprehensiveness. CONCLUSIONS Paid versions of ChatGPT remain the highest quality and most versatile option of available LLMs. These tools cannot replace expert input but serve as powerful assistants, streamlining the development process and enhancing productivity. CLINICALTRIAL n/a
- 28 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessLeveraging Artificial Intelligence Large Language Models for Writing Clinical Trial Proposals in Dermatology (Preprint)
BACKGROUND Large language models (LLMs) are becoming increasingly popular in clinical trial design but have been underutilized in research proposal development. OBJECTIVE This study compares the performance of commonly used open access LLMs versus human proposal composition and review. METHODS Ten LLMs were prompted to write a research proposal. Six physicians and each of the LLMs assessed 11 blinded proposals for capabilities and limitations in accuracy and comprehensiveness. RESULTS Chat GPT o1 was rated the most accurate and LLaMA 3.1 the least accurate by human scorers. LLM scorers rated Chat GPT o1 and Deepseek R1 the most accurate. Chat GPT o1 was the most comprehensive and LLaMA 3.1 the least comprehensive by human and LLM scorers. LLMs performed poorly on scoring proposals, and on average rated proposals 1.9 points higher than humans for both accuracy and comprehensiveness. CONCLUSIONS Paid versions of ChatGPT remain the highest quality and most versatile option of available LLMs. These tools cannot replace expert input but serve as powerful assistants, streamlining the development process and enhancing productivity. CLINICALTRIAL n/a
- Open Access
- 20 February 2025
- Published by Wiley in Histopathology
- Vol. 87 (1) , 110-129
Role of single‐nucleotide polymorphism microarray in the classification of BAP1‐inactivated melanocytic tumours
Aims: BAP1‐inactivated melanocytic tumours (BIMTs) occur sporadically and in association with a familial tumour predisposition syndrome involving germline mutations in the BRCA1‐associated protein‐1 (BAP1) gene. Here we report the clinical features, histopathologic findings, and chromosomal copy number data of 19 BAP1‐inactivated melanocytomas (BIMs) and compare their features to those of five BAP1‐inactivated melanomas.Methods: We retrospectively searched the Department of Pathology archives and EMERSE (Electronic Medical Record Search Engine) for BIMTs that had undergone single‐nucleotide polymorphism (SNP) microarray testing. Clinical history/follow‐up data, detailed histopathologic features, and SNP microarray results were recorded.Results: Overall, four patients (4/13) with BIMs and available clinical history had features suspicious for a germline BAP1 aberration. In BIMs (19 cases), the BAP1‐inactivated component showed variable cytologic features, including epithelioid (predominant), rhabdoid, plasmacytoid, and nevoid morphologies. Sentinel lymph node biopsy was negative in all (6/6) patients in which this procedure was performed. No patient diagnosed with a BIM with available clinical follow‐up (18/19; mean 38 months) experienced an adverse event. While the histologic appearances of the five melanomas varied, one case resembled a BIM. The median mitotic count was 1/mm2 (range 0–6 mm2) in BIMs compared to 3/mm2 (range 1–4/mm2) in melanomas (P = 0.04). The median number of copy number alterations (CNAs) was two (range 0–6) in indolent cases versus seven (range 6–10) in melanomas (P = 0.0005). The most common molecular aberration after loss of 3p21 was heterozygous loss of the CDKN2A locus, which unlike homozygous loss has not been associated with melanoma.Conclusion: While most BIMs appear to have a favourable prognosis, even those with multiple CNAs, they deserve careful integration of all clinical and pathologic findings. Although not fully diagnostic, a mitotic count of ≥3/mm2 and ≥6 CNAs in the appropriate context is supportive of a diagnosis of BAP1‐inactivated melanoma.
- 20 February 2025
- Published by Wiley in Histopathology
- Vol. 87 (1) , 110-129
Open AccessRole of single‐nucleotide polymorphism microarray in the classification of BAP1‐inactivated melanocytic tumours
Aims: BAP1‐inactivated melanocytic tumours (BIMTs) occur sporadically and in association with a familial tumour predisposition syndrome involving germline mutations in the BRCA1‐associated protein‐1 (BAP1) gene. Here we report the clinical features, histopathologic findings, and chromosomal copy number data of 19 BAP1‐inactivated melanocytomas (BIMs) and compare their features to those of five BAP1‐inactivated melanomas.Methods: We retrospectively searched the Department of Pathology archives and EMERSE (Electronic Medical Record Search Engine) for BIMTs that had undergone single‐nucleotide polymorphism (SNP) microarray testing. Clinical history/follow‐up data, detailed histopathologic features, and SNP microarray results were recorded.Results: Overall, four patients (4/13) with BIMs and available clinical history had features suspicious for a germline BAP1 aberration. In BIMs (19 cases), the BAP1‐inactivated component showed variable cytologic features, including epithelioid (predominant), rhabdoid, plasmacytoid, and nevoid morphologies. Sentinel lymph node biopsy was negative in all (6/6) patients in which this procedure was performed. No patient diagnosed with a BIM with available clinical follow‐up (18/19; mean 38 months) experienced an adverse event. While the histologic appearances of the five melanomas varied, one case resembled a BIM. The median mitotic count was 1/mm2 (range 0–6 mm2) in BIMs compared to 3/mm2 (range 1–4/mm2) in melanomas (P = 0.04). The median number of copy number alterations (CNAs) was two (range 0–6) in indolent cases versus seven (range 6–10) in melanomas (P = 0.0005). The most common molecular aberration after loss of 3p21 was heterozygous loss of the CDKN2A locus, which unlike homozygous loss has not been associated with melanoma.Conclusion: While most BIMs appear to have a favourable prognosis, even those with multiple CNAs, they deserve careful integration of all clinical and pathologic findings. Although not fully diagnostic, a mitotic count of ≥3/mm2 and ≥6 CNAs in the appropriate context is supportive of a diagnosis of BAP1‐inactivated melanoma.
- Open Access
- 9 November 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (12) , 3027-3029
Hair follicle stem cells and the collapse of self-tolerance in alopecia: the interplay of barrier function, the microbiome, and immunity
The hair follicle is thought to be a site of ‘immune privilege,’ or relative protection from autoimmune and inflammatory responses. In particular, the long-lived, quiescent hair follicle stem cells (HFSCs) are strikingly resistant to cytotoxic immune effectors such as T cells and natural killer (NK) cells, even in systems where these cells are artificially directed to attack HFSCs. Nonetheless, many forms of alopecia are associated with immune-mediated damage of the hair follicle epithelium, suggesting a failure of immune privilege. What precipitates the collapse of HFSC immune privilege in alopecia? In this current issue of EMBO Molecular Medicine, Strobl et al use an innovative mouse model to add to our mechanistic understanding of this disorder (Strobl et al, 2024).
- 9 November 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (12) , 3027-3029
Open AccessHair follicle stem cells and the collapse of self-tolerance in alopecia: the interplay of barrier function, the microbiome, and immunity
The hair follicle is thought to be a site of ‘immune privilege,’ or relative protection from autoimmune and inflammatory responses. In particular, the long-lived, quiescent hair follicle stem cells (HFSCs) are strikingly resistant to cytotoxic immune effectors such as T cells and natural killer (NK) cells, even in systems where these cells are artificially directed to attack HFSCs. Nonetheless, many forms of alopecia are associated with immune-mediated damage of the hair follicle epithelium, suggesting a failure of immune privilege. What precipitates the collapse of HFSC immune privilege in alopecia? In this current issue of EMBO Molecular Medicine, Strobl et al use an innovative mouse model to add to our mechanistic understanding of this disorder (Strobl et al, 2024).